YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells

BACKGROUND AND PURPOSE: The aim of this study was to determine the potency and molecular mechanism of action of YM155, a first-in-class survivin inhibitor that is currently under phase I/II clinical investigations, in various drug-resistant breast cancers including the oestrogen receptor positive (E...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Pharmacol
Autors principals: Cheng, S M, Chang, Y C, Liu, C Y, Lee, J Y C, Chan, H H, Kuo, C W, Lin, K Y, Tsai, S L, Chen, S H, Li, C F, Leung, E, Kanwar, J R, Huang, C C, Chang, J Y, Cheung, C H A
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Publishing Ltd 2015
Matèries:
Research Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4280979/
https://ncbi.nlm.nih.gov/pubmed/25220225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.12935
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars